This study investigates the combination of an investigational medication with immunotherapy and chemotherapy in patients who have undergone surgery for pancreatic cancer.
The study evaluates the safety and effectiveness of this treatment combination. It seeks to understand how well patients tolerate the treatment.
- Who can participate: Adults aged 18 to 75 years who have completed an R0 or R1 surgical resection for pancreatic cancer can participate. Key eligibility includes no previous therapy before surgery and good organ function.
- Study details: Participants will receive an investigational medication along with other treatments. Some may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.